STOCK TITAN

DAXOR Stock Price, News & Analysis

DXR NASDAQ

Company Description

Company Overview

Daxor Corp (DXR) is a medical instrumentation and biotechnology company that pioneers accurate blood volume measurement. The company specializes in diagnostic instrumentation that provides a precise assessment of blood volume status, a crucial factor in patient fluid management and clinical diagnostics. In an industry where traditional methods have been cumbersome and imprecise, Daxor Corp has innovated a solution that addresses a critical gap in medical evaluations.

The BVA-100 Technology

At the heart of Daxor Corp's innovation is the BVA-100 (Blood Volume Analyzer). This diagnostic device is the first of its kind to be cleared by the FDA for delivering safe and objective quantification of blood volume. Unlike traditional tests that could take several hours and often relied on indirect measurements such as blood thickness, the BVA-100 offers a direct, rapid, and reliable assessment. This technological breakthrough not only enhances the accuracy of patient evaluations but also simplifies the diagnostic process for healthcare providers.

Market Impact and Clinical Significance

Accurate measurement of blood volume is essential in a variety of clinical settings, especially in surgeries and conditions that require optimal fluid management. Daxor Corp's innovative approach enables healthcare professionals to obtain critical physiological information quickly, contributing to improved patient care. By delivering fast and reliable diagnostic results, Daxor Corp has established its significance in the clinical diagnostics landscape where every moment and measurement matters.

Competitive Position and Expertise

Daxor Corp operates in a competitive sector of medical instrumentation where precision and reliability are paramount. The company differentiates itself with its dedicated focus on blood volume measurement, a niche with substantial unmet needs. The BVA-100's FDA clearance further reinforces its authority in the diagnostic market. This specialized approach not only addresses a critical clinical demand but also positions Daxor Corp as a knowledgeable and trusted entity within the medical technology community.

Commitment to Advancing Healthcare

With a mission centered on enhancing clinical outcomes, Daxor Corp has implemented a strategy that emphasizes research, development, and strategic product innovation. The company’s continuous improvement of diagnostic tools such as the BVA-100 underscores its commitment to advancing healthcare. Through rigorous clinical validations and adherence to stringent regulatory standards, Daxor Corp enables healthcare practitioners to make better-informed decisions, ensuring optimal fluid management in diverse medical scenarios.

Operational Excellence and Industry Integration

Daxor Corp's operations are characterized by a blend of scientific expertise and operational rigor. Its technology is integrated within an ecosystem of healthcare diagnostics, where the direct measurement of blood volume is vital for effective patient management. The company's approach is rooted in enhancing the reliability of diagnostic tests, establishing a clear value proposition that combines innovative technology with practical clinical applications. This positions Daxor Corp as a strategic player within the broader realms of medical instrumentation and biotechnology.

Overall, Daxor Corp's robust framework in precision diagnostics and its focus on a specialized, clinically significant measurement process provide an informative insight for investors and industry observers. Its methodical and data-driven approach to overcoming diagnostic challenges is a clear reflection of its depth of knowledge and commitment to excellence in healthcare technology.

Stock Performance

$7.45
0.00%
0.00
Last updated: April 29, 2025 at 15:24
-24.63 %
Performance 1 year
$39.4M
Market Cap
4.9M
Shares outstanding

SEC Filings

No SEC filings available for DAXOR.

Financial Highlights

$1,446,345
Revenue (TTM)
-$7,185,639
Net Income (TTM)
-$6,508,648
Operating Cash Flow
-496.81%
Net Profit Margin
-400.07%
Oper. Profit Margin
54.89%
Gross Profit Margin

Upcoming Events

Frequently Asked Questions

What is the current stock price of DAXOR (DXR)?

The current stock price of DAXOR (DXR) is $7.4542 as of April 29, 2025.

What is the market cap of DAXOR (DXR)?

The market cap of DAXOR (DXR) is approximately 39.4M.

What is the revenue (TTM) of DAXOR (DXR) stock?

The trailing twelve months (TTM) revenue of DAXOR (DXR) is $1,446,345.

What is the net income of DAXOR (DXR)?

The trailing twelve months (TTM) net income of DAXOR (DXR) is -$7,185,639.

What is the operating cash flow of DAXOR (DXR)?

The operating cash flow of DAXOR (DXR) is -$6,508,648.

What is the profit margin of DAXOR (DXR)?

The net profit margin of DAXOR (DXR) is -496.81%.

What is the operating margin of DAXOR (DXR)?

The operating profit margin of DAXOR (DXR) is -400.07%.

What is the gross margin of DAXOR (DXR)?

The gross profit margin of DAXOR (DXR) is 54.89%.

What is the current ratio of DAXOR (DXR)?

The current ratio of DAXOR (DXR) is 1.66, indicating the company's ability to pay short-term obligations.

What is the gross profit of DAXOR (DXR)?

The gross profit of DAXOR (DXR) is $793,834 on a trailing twelve months (TTM) basis.

What is the operating income of DAXOR (DXR)?

The operating income of DAXOR (DXR) is -$5,786,414.

What is the core business of Daxor Corp?

Daxor Corp focuses on developing innovative medical instrumentation, specifically targeting precise blood volume measurement using its BVA-100 device.

How does the BVA-100 differentiate itself from traditional tests?

The BVA-100 offers rapid, accurate, and objective measurement of blood volume, addressing the shortcomings of traditional methods that were lengthy and often imprecise.

What clinical benefits does accurate blood volume measurement provide?

Accurate blood volume measurement supports optimal fluid management, improves patient care during surgical and medical procedures, and provides essential data for clinical decision-making.

How is Daxor Corp positioned in the medical instrumentation industry?

Daxor Corp occupies a specialized niche by focusing on blood volume measurement, backed by FDA clearance and a commitment to technological innovation, which distinguishes its approach in the diagnostic market.

What are the key features of Daxor Corp's diagnostic technology?

Key features include precision, reliability, and speed in blood volume measurement, which are critical for effective fluid management and accurate patient diagnostics.

How does Daxor Corp ensure the reliability of its diagnostic instruments?

The company adheres to rigorous clinical validations and regulatory standards, ensuring its instruments deliver consistent, objective data for improved clinical outcomes.

What challenges does Daxor Corp address with its technology?

Daxor Corp addresses the longstanding challenge of lengthy and imprecise blood volume tests, offering a solution that combines rapid measurement with exceptional accuracy.

In what ways does Daxor Corp maintain its competitive edge?

By focusing on a niche diagnostic area and continuously innovating its product offerings, Daxor Corp sustains its competitive advantage through technological excellence and compliance with stringent regulatory standards.